A Randomized, Double Blind, Multicentre Study to Evaluate Safety and Immunogenicity of Four Fluval AB-Like Influenza Vaccines With 3.5 microgHA, 6 microgHA, 9 microgHA Or 15 microgHA Of A/H1N1, A/H3N2 and B Influenza Antigens in Adult and Elderly Subjects.

Trial Profile

A Randomized, Double Blind, Multicentre Study to Evaluate Safety and Immunogenicity of Four Fluval AB-Like Influenza Vaccines With 3.5 microgHA, 6 microgHA, 9 microgHA Or 15 microgHA Of A/H1N1, A/H3N2 and B Influenza Antigens in Adult and Elderly Subjects.

Completed
Phase of Trial: Phase II

Latest Information Update: 15 Sep 2017

At a glance

  • Drugs Influenza virus vaccine (Primary)
  • Indications Influenza A virus H1N1 subtype; Influenza A virus H3N2 subtype; Influenza B virus infections
  • Focus Pharmacodynamics
  • Sponsors Fluart Innovative Vaccines
  • Most Recent Events

    • 21 Oct 2011 Actual end date Oct 2011 added as reported by ClinicalTrials.gov.
    • 21 Oct 2011 Status changed from not yet recruiting to completed as reported by ClinicalTrials.gov.
    • 01 Sep 2011 Planned initiation date changed from 1 Aug 2011 to 1 Sep 2011 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top